{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:31:42Z","timestamp":1747168302100,"version":"3.40.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.neurol.2024.08.005","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T12:29:19Z","timestamp":1726748959000},"page":"888-894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Strategies to improve autoimmune neurological diseases treatment"],"prefix":"10.1016","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8972-515X","authenticated-orcid":false,"given":"F.","family":"Leypoldt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2024.08.005_bib0105","doi-asserted-by":"crossref","first-page":"5534851","DOI":"10.1155\/2021\/5534851","article-title":"Update in the management of ANCA-associated vasculitis: recent developments and future perspectives","volume":"2021","author":"Samman","year":"2021","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.neurol.2024.08.005_bib0110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/bioengineering10020176","article-title":"Hematopoietic stem cell transplantation for the treatment of autoimmune neurological diseases: an update","volume":"10","author":"Mariottini","year":"2023","journal-title":"Bioengineering"},{"key":"10.1016\/j.neurol.2024.08.005_bib0115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases","volume":"23","author":"Haghikia","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.08.005_bib0120","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.neurol.2024.08.005_bib0125","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult Scler J"},{"issue":"8","key":"10.1016\/j.neurol.2024.08.005_bib0130","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"Stellmann","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"7","key":"10.1016\/j.neurol.2024.08.005_bib0135","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2024.08.005_bib0140","doi-asserted-by":"crossref","first-page":"113166","DOI":"10.1016\/j.celrep.2023.113166","article-title":"Human NMDAR autoantibodies disrupt excitatory-inhibitory balance, leading to hippocampal network hypersynchrony","volume":"42","author":"Ceanga","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.neurol.2024.08.005_bib0145","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ana.24721","article-title":"Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity","volume":"80","author":"Planaguma","year":"2016","journal-title":"Ann Neurol"},{"year":"2024","series-title":"Peripherally administered therapeutic one-armed antibody reversed behavioral abnormalities in a marmoset model of anti-NMDAR Encephalitis","author":"Matsumoto","key":"10.1016\/j.neurol.2024.08.005_bib0150"},{"key":"10.1016\/j.neurol.2024.08.005_bib0155","doi-asserted-by":"crossref","first-page":"107827","DOI":"10.1016\/j.neuropharm.2019.107827","article-title":"Affinity-matured \u201caquaporumab\u201d anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders","volume":"162","author":"Duan","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neurol.2024.08.005_bib0160","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2024.08.005_bib0165","doi-asserted-by":"crossref","first-page":"e1088","DOI":"10.1212\/NXI.0000000000001088","article-title":"Rituximab treatment and long-term outcome of patients with autoimmune encephalitis","volume":"8","author":"Thaler","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.005_bib0170","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T\u00a0cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.neurol.2024.08.005_bib0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/cei\/uxae031","article-title":"Disrupting B and T-cell colaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?","volume":"217","author":"Shah","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.neurol.2024.08.005_bib0180","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2311049121","article-title":"Ultrahigh frequencies of peripherally matured LGI1- and CASPR2-reactive B cells characterize the cerebrospinal fluid in autoimmune encephalitis","volume":"121","author":"Theorell","year":"2024","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.neurol.2024.08.005_bib0185","article-title":"CSF plasma cell expansion in LGI1-\/CASPR2-autoimmune encephalitis is associated with loss of regulatory MAIT cells","author":"Esser","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.neurol.2024.08.005_bib201","doi-asserted-by":"crossref","unstructured":"Saggau C., Bacher P., Esser D., Rasa M., Meise S., Mohr N., et al. Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases. Immunity. 2024. doi: 10.1016\/j.immuni.2024.08.005. [S1074-7613(24)00404-7. Epub ahead of print. PMID: 39226901]","DOI":"10.1016\/j.immuni.2024.08.005"},{"key":"10.1016\/j.neurol.2024.08.005_bib0190","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1007\/s00415-020-10371-y","article-title":"Decreased inflammatory cytokine production of antigen-specific CD4+ T cells in NMDA receptor encephalitis","volume":"268","author":"Dao","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2024.08.005_bib0195","doi-asserted-by":"crossref","first-page":"e1085","DOI":"10.1212\/NXI.0000000000001085","article-title":"Genome-wide association study identifies 2 new Loci associated with anti-NMDAR encephalitis","volume":"8","author":"Tietz","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2024.08.005_bib0200","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.3355","article-title":"Real-world evidence to support EU Regulatory Decision making\u2014results from a pilot of regulatory use cases","author":"Prilla","year":"2024","journal-title":"Clin Pharmacol Ther"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724005897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724005897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T17:35:53Z","timestamp":1730396153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378724005897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0035378724005897"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2024.08.005","relation":{},"ISSN":["0035-3787"],"issn-type":[{"type":"print","value":"0035-3787"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies to improve autoimmune neurological diseases treatment","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2024.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}